Astellas Pharma Inc.

Astellas Pharma Inc. announced it will acquire Iota Biosciences, Inc., a start-up company with unique ultrasonic-powered bioelectronic devices technology. The acquisition is expected to accelerate Astellas' Rx+ business by acquiring innovative technology for ultra-small implantable medical devices.

Astellas Pharma announced the construction of a new manufacturing facility for the active pharmaceutical ingredient of Prograf at its Toyama Technology Center in Japan. The total construction cost is approximately ¥10.0 billion, with construction starting in April 2020 and completion scheduled for August 2021.

Astellas Pharma Inc. announced the start of construction of new research, development and manufacturing facilities for drugs using innovative modalities including antibodies and cell therapies in Toyama and Tsukuba, Japan, and Massachusetts, United States.